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To evaluate changes in myocardial energetics and sys-
temic and cardiac sympathetic activity associated with 
improved left ventricular function after MOL 17043, a 
new inotropic vasodilator agent, systemic and coronary 
hemodynamics and myocardial catecholamine balance 
were determined in 17 patients with severe heart failure. 
After the administration of MOL 17043, cardiac index 
increased by 67% and pulmonary capillary wedge pres-
sure decreased (25 ± 5 to 14 ± 7 mm Hg, p < 0.01), 
indicating improved left ventricular function. Coronary 
sinus blood flow (75 ± 29 to III ± 51 ml/min, p < 0.01) 
and myocardial oxygen consumption (9.9 ± 3.3 to ll.S 
± 5.4 ml/min, p < 0.05) increased despite decreased 
myocardial oxygen extraction (11.7 ± 2 to 10.1 ± 3.3 
New pharmacologic agents with both vasodilating and pos-
itive inotropic properties have been demonstrated to improve 
cardiac function in patients with severe heart failure refrac-
tory to conventional therapy (1,2). MOL 17043. a nongly-
coside, noncatecholamine, imidazole derivative (1,3 di-
hydro -4 - methyl- 5 - [4 - (methylthio) benzoyl] - 2H - imidazole-
2-one), possesses both positive inotropic and vasodilating 
effects and improves left ventricular function of patients with 
severe heart failure (3). However, whether this improvement 
in left ventricular function is accompanied by a change in 
cardiac sympathetic tone or myocardial metabolic cost has 
not been adequately evaluated. The purpose of this study, 
therefore, was to determine changes in myocardial cate-
cholamine balance, coronary hemodynamics and left ven-
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vol %, P < 0.05) and a higher coronary sinus oxygen 
content. Although transmyocardiallactate extraction re-
mained unchanged, increased myocardial oxygen con-
sumption has potential deleterious effects on myocardial 
metabolic function. Arterial norepinephrine concentra-
tions and transmyocardial norepinephrine release also 
remained unchanged. 
These findings suggest that MOL 17043 improves left 
ventricular pump function, but produces no detectable 
change in systemic and cardiac sympathetic activity. Im-
proved left ventricular function is associated with in-
creased myocardial oxygen consumption despite pri-
mary coronary vasodilation. 
(J Am Coll CardioI1985;5:326-32) 
tricular function during MOL 17043 therapy in patients with 
severe chronic heart failure. 
Methods 
Study patients. Seventeen patients formed the study 
group. There were 12 men and 5 women with a mean age 
of 57 ± 10 years (range 42 to 69). All patients had clinical 
evidence of heart failure, radiologic evidence of cardiomeg-
aly and pulmonary venous and arterial hypertension. The 
cause of heart failure was ischemic cardiomyopathy in 13 
patients and dilated congestive cardiomyopathy in the re-
maining 4 patients. At the time of investigation, 14 patients 
were in New York Heart Association functional class IV 
and 3 were in class III. Eleven patients had a prior myo-
cardial infarction and six gave a history of hypertension; 
however, no patient had hypertension at the time of the 
study. Fourteen patients were taking digitalis and 16 were 
on diuretic therapy. Vasodilators. including nitrates, were 
discontinued at least 24 hours before study. 
Hemodynamic and metabolic studies. Patients were 
studied in the resting, nonsedated state in the cardiac care 
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unit of Moffitt Hospital at the University of California. San 
Francisco. Written informed consent was obtained from all 
patients. A triple lumen thermistor Swan-Ganz catheter was 
positioned in the pulmonary artery percutaneously through 
the subclavian vein. to measure cardiac output and right 
atrial. pumonary arterial and pulmonary capillary wedge 
pressures (4). Cardiac output was determined by the ther-
modilution technique. The radial artery was cannulated for 
direct measurement of the arterial pressure. Under fluoro-
scopic guidance. a double thermistor catheter (Wilton-Web-
ster Laboratories) was placed percutaneously in the coronary 
sinus. To minimize coronary sinus reflux, the catheter was 
advanced into the midcoronary sinus and its position checked 
by a small bolus injection of contrast medium (5). 
Coronary sinus flow was determined by constant infusion 
thermodilution (6) using the formula: 
Coronary sinus flow (mllmin) 
B I ~ I x I.OX x 46. (
T ~ T ) 
Til ~ TM 
where T B = temperature of the blood; T, = temperature 
of the indicator; T M = temperature of the mixture of the 
blood and indicator; 1.08 = a constant accounting for spe-
cific heat and density of blood and the indicator; 46 = the 
injection rate (mllmin) of the indicator (5% dextrose in 
water) through a Harvard constant infusion pump. We pre-
viously reported (7) the reproducibility of measurements of 
coronary sinus flow. When estimated by computing the dif-
ference in mean values (± standard deviation) of those 
measurements where the baseline heart rate-systolic blood 
pressure product varied no more than 10%. the difference 
in coronary sinus flow was 0.1 ± 4.02 mllmin. 
After a rest period of at least 30 minutes following the 
positioning of the catheters. blood was drawn simulta-
neously from the coronary sinus and the radial artery for 
determination of catecholamine concentrations. oxygen sat-
uration and lactate concentration. Systemic hemodynamics. 
cardiac output and coronary sinus flow were then determined. 
Plasma epinephrine and norepinephrine were measured 
with the radioenzymatic technique using a modified method 
of Peuler and Johnson (8). Replicate measurements in our 
laboratory of plasma epinephrine and norepinephrine have 
a coefficient of variation of 7 and II %. respectively. Normal 
laboratory values in supine subjects are as follows: epi-
nephrine. 35 to 165 pg/ml; norepinephrine. 100 to 550 pg/ml 
(both + 3 standard deviations). 
The lactate concentration was measured by the enzymatic 
fluorometric method of Loomis (9) and oxygen saturation 
was measured with a Corning 175 automated blood and pH 
analyzer. 
Calculations. The hemodynamic and metabolic vari-
ables were calculated as follows: 
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Oxygen content (vol %) = Oxygen saturation x Hemo-
globin x 1.34. 
Myocardial oxygen extraction (vol %) = Arterial oxygen 
content - Coronary sinus oxygen content. 
Myocardial oxygen consumption (mllmin) = Arterialox-
ygen content - Coronary sinus oxygen content x Coronary 
sinus flow x 10 - 2. 
Myocardial oxygen delivery (mllmin) = Arterial oxygen 
content X Coronary sinus flow x 10' 2. 
Mvocardial lactate extraction (%) 
(
Arterial - Coronary Sinus) 
lactate x 100. 
Arterial 
Cardiac index (liters/min per m2 ) = Cardiac output/Body 
surface area. 
Stroke volume index (mllm2) = Cardiac index/Heart rate. 
Stroke work index (g-m/m2) = (Mean systolic arterial 
pressure - Mean pulmonary capillary wedge pressure) x 
Stroke volume index x 0.0136. 
Svstemic vascular resistance (dynes's'cm ') = [(Mean 
arterial pressure ~ Mean right atrial pressure)/Cardiac out-
put! x 80. 
Pulmonary vascular resistance (dynes·s·cm- s) = [(Mean 
pulmonary artery pressure - Mean right atrial pres-
sure)/Cardiac output] X 80. 
Net transmyocardial epinephrine release (pg/min) = 
(Arterial - Coronary sinus) epinephrine x Coronary sinus 
flow. 
Net tram'myocardial norepinephrine release (pg/min) = 
(Arterial - Coronary sinus) norepinephrine x Coronary 
sinus flow. 
MDL 17043 administration and repeat measure-
ments. After the control measurements. MOL 17043 was 
administered by slow intravenous infusion every 15 minutes 
in doses of 0.5, 1.0 and 1.5 mg/kg. Hemodynamic variables 
were measured immediately after each dose and at approx-
imately 10 minutes after each dose. Subsequent doses of 
1.5 mg/kg were administered at IS minute intervals until 
cardiac output response stabilized. heart rate increased by 
more than 15% or to 120 beats/min. systolic blood pressure 
decreased by more than 20% or below 85 mm Hg, pul-
monary capillary wedge pressure decreased to less than 10 
mm Hg or a cumulative dose of 10 mg/kg was administered. 
Peak effect was defined when the maximal increase in car-
diac output was achieved and after which no further sig-
nificant increment occurred on the basis of the degree of 
variability in determination of cardiac output in the group 
(6Yk, confidence limits). 
At the time when there was no further increase in cardiac 
output. coronary sinus. venous and arterial blood samples 
were drawn simultaneously for repeat measurements of cate-
cholamine concentrations. oxygen saturation and lactate 
concentration. Systemic hemodynamics and coronary sinus 
flow were then determined. 
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Table 1. Changes in Systemic Hemodynamic Effects in 17 Patients With Severe Heart Failure 
After MOL 17043 
Heart rate (beats/min) 
Mean blood pressure (mm Hg) 
Mean right atrial pressure (mm Hg) 
Mean pulmonary artery pressure (mm Hg) 
Pulmonary capillary wedge pressure (mm Hg) 
Cardiac index (liters/min per m') 
Stroke volume index (mllm') 
Pulmonary vascular resistance (dynes's'cm ') 
Systemic vascular resistance (dynes·s'cm ') 
Stroke work index (g-m/beats per m') 
Data are reported as mean :+: standard deviation. 
Statistics. The paired ( test was used to determine the 
statistical significance of the difference in variables at base-
line and at peak effect. The confidence intervals for the 
measured differences were calculated as follows (10): 
Difference = Measured difference ± tUI2~' 
where (l' = 0.05 to produce 95% confidence intervals; {ern 
= t value for n - I degrees of freedom; s = standard de-
viation of the differences and n = number of pairs. 
Results 
Changes in systemic hemodynamics. The systemic 
hemodynamic effects of intravenous MOL 17043 in all 17 
patients are summarized in Table I. The mean cumulative 
dose of MOL 17043 administered was 3.6 mg/kg (range 0.5 
to 10). The mean time to peak drug effect was 27 minutes. 
After the administration of MOL 17043, there was a 
statistically significant increase in heart rate and a decrease 
in mean arterial pressure; however, these changes were small. 
There was a marked decrease in right atrial, pulmonary 
arterial and pulmonary capillary wedge pressures and in 
pulmonary and systemic vascular resistance. Cardiac index 
( + 67%), stroke volume index (+ 46%) and stroke work 
Baseline 
84 :+: 12 
78 :+: II 
13 :+: 8 
38 :+: 7 
25 :+: 5 
2.1 :+: 0.7 
26 ± 9 
284 :+: 143 
1,450 :+: 567 
27 :+: 14 
Peak 
93 :+: 15 
70 :+: 7 
8 :+: 7 
28 :+: 8 
14 :+: 7 
3.5 :+: 0.9 
38 :+: 9 
207 :+: 103 
868 :+: 296 
41 :+: 14 
p Value 
<0.01 
«Ull 
«Ull 
«Ull 
«Ull 
<0.01 
«Ull 
<0.05 
<0.01 
«Ull 
index ( + 52%) increased in all patients along with a decrease 
in pulmonary capillary wedge pressure, indicating improved 
left ventricular pump performance. 
Changes in coronary hemodynamics. The changes in 
coronary hemodynamics and myocardial metabolic function 
are summarized in Table 2. In 12 of 16 patients, coronary 
sinus blood flow increased (Fig. I), and in the group as a 
whole, this increase was significant (p < 0.0 I). Heart rate-
systolic blood pressure product tended to be higher after 
MOL 17043, although these changes were not statistically 
significant. Myocardial oxygen extraction, determined in 16 
of 17 patients, tended to decrease, partly because of a slight 
but statistically significant decrease in arterial oxygen con-
tent (Fig. 2). However, in II of 16 patients, coronary sinus 
oxygen content was higher (Fig. 3). Calculated myocardial 
oxygen delivery increased significantly and, despite a lower 
myocardial oxygen extraction, myocardial oxygen con-
sumption increased. Transmyocardiallactate extraction was 
unchanged. Myocardial lactate production did not occur in 
any patient after the administration of MOL 17043. In one 
patient, lactate production was observed both before and 
after MOL 17043. 
Myocardial catecholamine balance. The changes in ar-
terial and coronary sinus venous catecholamine concentation 
and myocardial catecholamine balance after MOL 17043 
administration are summarized in Table 3. Coronary sinus 
Table 2. Changes in Coronary Hemodynamics in 17 Patients With Severe Heart Failure After 
MOL 17043 
Baseline Peak p Value 
Myocardial oxygen extraction (vol %) 11.7 :+: 2.0 10.1 :+: 3.3 <0.05 
Myocardial oxygen delivery (m\!min) 12.0 :+: 4.3 16.4 :+: 9.6 <0.05 
Myocardial oxygen consumption (ml/min) 8.9 :+: 3.3 11.8 :+: 5.4 <0.05 
Lactate extraction (%) 27:+: 19 21 :+: 19 NS 
Coronary sinus flow (ml/min) 75 :+: 29 III :+: 51 <0.01 
HR x SBP x 10 3 (mm Hg/min) 8.9 :+: 1.5 10.4 :+: 1.9 NS 
Data are reported as mean:+: standard deviation. HR = heart rate; NS = not significant; SBP = systolic 
blood pressure. 
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Figure 1. Changes in coronary sinus blood flow (mlimin) after 
MOL 17043 in 16 patients with severe heart failure. In 12 of the 
16 patients, coronary sinus blood flow increased and left ventricular 
function improved. The dashed line indicates the average increase 
in coronary sinus blood flow from 75 ::':: 29 to III ± 51 ml/min. 
venous epinephrine concentrations were lower than arterial 
epinephrine concentrations both before and after MOL 17043. 
and myocardial epinephrine balance (uptake) was un-
changed. Coronary sinus venous norepinephrine concentra-
tions. however, were higher than arterial norepinephrine 
values. There was no statistically significant change in net 
myocardial norepinephrine release (change of 1.41 x 104 
pg/min with 15% confidence limits of + 0.99 x 104 to 
- 3.8 x W~ pg/min). Arterial norepinephrine concentra-
tions were higher than those found in subjects without heart 
failure, but there was no statistically significant change after 
MOL 17043 (change of - 59 pg/ml with 9Y'lc confidence 
limits of + 194 to - 312 pg/ml). 
VIQUERAT ET AL. 329 
CORONARY HEMODYNAMICS AFTER MDL 17043 
Discussion 
Systemic hemodynamics. This study confirms that MOL 
17043 administered intravenously produces marked im-
provement in left ventricular function in patients with severe 
chronic congestive heart failure (3). Enhanced left ven-
tricular pump function was evident from the concomitant 
increase in cardiac index, stroke volume and stroke work 
indexes and marked decrease in pulmonary capillary wedge 
pressure. This study, however, does not elucidate the po-
tential mechanisms for improved left ventricular function 
with MOL 17043, except that the reduction of left ventric-
ular outflow resistance must have been contributory since 
there was a marked reduction in systemic vascular resistance 
and some decrease in arterial pressure. 
Coronary hemodynamics. This study also suggests that 
improved left ventricular function is associated with in-
creased myocardial oxygen consumption. Coronary sinus 
blood flow and total myocardial oxygen delivery increased 
in our patients after the administration of MOL 17043. The 
increase in coronary sinus flow determined by thermodi-
lution technique cannot be explained by the changes in coro-
nary sinus reflux (5) because after MOL 17043, there was 
a significant reduction in right atrial pressure which should 
be associated with decreased coronary sinus reflux. Thus, 
the increase in coronary sinus flow after the administration 
of MOL 17043 in these patients was probably underestimated. 
Increased myocardial oxygen requirements and in-
creased cardiac h/ood flow. A decreased myocardial oxy-
gen extraction after MOL 17043 was partly caused by de-
creased arterial oxygen content, presumably due to a marked 
increase in cardiac output and transpulmonary shunt. How-
ever, the decrease in myocardial oxygen extraction was 
primarily due to the increased coronary sinus venous oxygen 
content. The reduction in myocardial oxygen extraction and 
a higher coronary sinus venous oxygen content, in most of 
our patients, raises the possibility that the drug-induced 
primary decrease in coronary vascular resistance is a pos-
sible mechanism for increased coronary blood flow. Where 
the increment in coronary blood flow occurs entirely because 
of an increased myocardial oxygen requirement, the global 
myocardial oxygen extraction either remains unchanged or 
increases; the coronary sinus venous oxygen content also 
remains unchanged or decreases. Thus, a decreased myo-
cardial oxygen extraction and a higher coronary sinus ve-
nous oxygen content strongly suggest primary coronary va-
sodilation by MOL 17043. Because myocardial oxygen con-
sumption also increased, however, the increase in coronary 
blood flow also must have resulted from the concomitant 
increase in myocardial oxygen requirements. 
The mechanism j()r the increased myocardial oxygen de-
mand in these patients after MDL 17043 administration 
remains unclear. Peak systolic arterial pressure or heart rate-
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Figure 2. Average changes in coronary sinus 
flow (CSF), arterial oxygen content (ART 0 1), 
coronary sinus oxygen content (CS 0 1), myo-
cardial oxygen delivery (MYOC 0, DELlV), 
myocardial oxygen consumption (MV02) and 
lactate extraction (LACTATE EXTRACT) after 
MOL 17043 in 16 patients with severe heart 
failure. Myocardial oxygen consumption in-
creased despite decreased arterial oxygen con-
tent and a higher coronary sinus oxygen content, 
suggesting that increased coronary sinus blood 
flow and myocardial oxygen delivery after MOL 
17043 were primarily related to increased myo-
cardial oxygen demand. 
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blood pressure product did not change significantly. How-
ever, there was a tendency to higher rate-pressure product, 
which might have contributed to increased myocardial ox-
ygen requirements. The changes in contractile function were 
not evaluated in this study. 
Ventricular function. In patients with heart failure, the 
first derivative of left ventricular pressure (dP/dt) increases 
despite a lower arterial pressure and unchanged heart rate, 
suggesting increased contractility (II). It appears, therefore, 
that MOL 17043 has the potential to increase contractile 
function, which might be contributory to increased myo-
cardial oxygen demand and consumption in patients with 
heart failure. 
In preliminary studies (12), it has been suggested that 
apparent left ventricular diastolic compliance may increase 
in some patients. We observed that in approximately 50% 
of patients with chronic heart failure, radioangiographically 
determined left ventricular volume increased after MOL 
17043 despite a marked decrease in pulmonary capillary 
wedge pressure. Although the mechanisms for such changes 
have not been elucidated, an increase in left ventricular 
diastolic volume with little or no decrease in arterial pressure 
is likely to increase left ventricular wall tension and, thus, 
myocardial oxygen demand and consumption in some pa-
tients. Further studies, however, will be required to deter-
mine the relative contributions of the changes in the different 
determinants of myocardial oxygen demand in increasing 
myocardial oxygen consumption after MOL 17043. 
n=16 _ - p<O.OI 
Myocardial lactate extraction and myocardial isch-
emia. In our patients, transmyocardiallactate extraction re-
mained unchanged despite increased myocardial oxygen 
consumption, indicating the lack of biochemical evidence 
for myocardial ischemia after MOL 17043. However, in a 
preliminary study, Martin et al. (13) reported that in some 
patients myocardial lactate production occurred after intra-
venous MOL 17043. These investigators also observed in-
creased coronary sinus blood flow and myocardial oxygen 
consumption and decreased myocardial oxygen extraction 
(results that were similar to those in our study). Martin et 
al. suggested that myocardial lactate production in some of 
their patients was due to intercoronary shunts since there 
was a decrease in myocardial oxygen extraction in the pres-
ence of increased myocardial oxygen consumption. How-
ever, an inadequate increase in coronary blood flow in re-
lation to the increase in myocardial oxygen demand in the 
relatively ischemic zone and an increase in flow in excess 
of metabolic demand in the non ischemic zones can also 
explain myocardial ischemia despite decreased global myo-
cardial oxygen extraction. It needs to be emphasized that 
regional myocardial ischemia may not be detected when one 
examines changes in global lactate extraction, as was done 
in this and previous studies. 
Myocardial catecholamine balance. That enhanced 
systemic and cardiac sympathetic tone accompany heart fail-
ure associated with low cardiac output has been documented 
(14-16). Arterial norepinephrine concentrations reflect sys-
l O.
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Figure 3. Changes in the coronary sinus oxygen content after 
MOL 17043 in 16 patients with severe heart failure. In II of the 
16 patients, coronary sinus oxygen content increased. suggesting 
primary coronary vasodilation by MOL 17043. NS = not significant. 
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temic sympathetic acttvIty, whereas changes in net myo-
cardial norepinephrine release can be used to assess cardiac 
sympathetic activity. In our patients, arterial norepinephrine 
concentration before MOL 17043 was higher than that ex-
pected in patients without heart failure (16). Net myocardial 
norepinephrine release was also greater than what has been 
reported in patients without heart failure. Thus, there was 
evidence for heightened systemic and cardiac sympathetic 
activity in our patients before MOL 17043. After the admin-
istration of MOL 17043, there was no change either in 
arterial norepinephrine concentration or in net myocardial 
norepinephrine release despite marked improvement in left 
ventricular function. Increased sympathetic activity has been 
regarded as a reflex response to depressed left ventricular 
function in patients with heart failure. Thus, improved left 
ventricular function with MOL 17043 was expected to de-
crease sympathetic activity in our patients. However.; de-
spite the marked increase in cardiac output and virtually no 
change in arterial pressure, arterial norepinephrine concen-
tration and net myocardial norepinephrine release remained 
unchanged after MOL 17043. 
These findings suggest that immediate improvement in 
left ventricular function with MOL 17043 is not associated 
with reflex decrease in systemic or cardiac sympathetic ac-
tivity. However, this is a short-term study and it remains 
to be determined whether there is a statistically significant 
change in catecholamine balance after a long-term improve-
ment in ventricular function. Also, the failure to detect a 
significant change must be interpreted with caution. Power 
analysis based on 95% confidence intervals shows that we 
cannot exclude a decrease from baseline of less than 300 
pg/ml for arterial norepinephrine and of less than 2.4 x 
104 pg/min for net transmyocardial norepinephrine release. 
Whether these magnitudes of decrease are clinically signif-
icant remains to be determined. This insensitivity for de-
tecting a decrease is due to a high standard deviation among 
the base to peak differences. 
Table 3. Changes in Circulating Catccholamines and Myocardial Catecholamine Balance in 17 
Patients With Severe Heart Failure After MOL 17043 
Baseline Peak p Value 
ART epinephrine 113 + 155 70 ± 87 NS 
(pg/ml) 
CS epinephrine 90+ 141 61 ± 82 NS 
(pg/ml) 
TmR epinephrine - 1.92 x 10' :+ 233 X 10' -1.00 X 10' ± 4.53 x 10' NS 
(pg/min) 
ART norepinephrine 846 + 744 787 ± 526 NS 
(pg/m!) 
CS norepinephrine 1,461 + 1.301 1.131 ± 996 NS 
(pg/m!) 
TmR norepinephrine 5.17 x 10" + 5.44 x 10" 3.D x 10" ± 6.78 x 10" NS 
(pg/ml) 
Data are reported as mean ± standard deviation. ART = arterial; CS = coronary sinus; NS = not 
significant; TmR = transmyocardial release. 
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Conclusion. The results of the present investigation sug-
gest that MDL 17043 improves left ventricular function in 
patients with severe refractory heart failure. Improved left 
ventricular function, however, is associated with increased 
myocardial oxygen consumption, which might have poten-
tial deleterious effects on myocardial metabolic function. 
Coronary vasodilation may also occur since there was de-
creased oxygen extraction and higher coronary sinus venous 
oxygen content in many patients after MOL 17043. Despite 
improved left ventricular function with MOL 17043, sys-
temic and cardiac sympathetic activity remains unchanged. 
References 
I. Benotti JR. Grossman W. Braunwald E. Davalds DO. Alousi AA. 
Hemodynamic assessment of amrinone. N Engl J Med 1978;299: 1373-7. 
2. Weber KT. Andrews V, Janicki JS. Cardiotonic agents in the man-
agement of chronic cardiac failure. Am Heart J 1982; 103:639-49. 
3. Uretsky BF. Generalovich T. Reddy PS. Spangenberg RB. Follansbee 
WP. The acute hemodynamic effects of a new agent. MDL 17043. 
in the treatment of congestive heart failure. Circulation 1983;67:823-8. 
4. Forrester JS, Ganz W. Diamond G. McHugh T. Chonette DW. Swan 
HJC. Thermodilution cardiac output determination with a single flow 
directed catheter. Am Heart J 1972;83:306-11. 
5. Mathey DG. Chatterjee K. Tyberg JV. Lekven J. Brundage B. Parmley 
WW. Coronary sinus reflux. Circulation I 97S;57:778-86. 
6. Ganz W. Tamura K. Marcus HS. Donoso RR, Yoshido S. Swan HJC. 
Measurement of coronary sinus blood flow by continuous thermodi-
lution in man. Circulation 1971:44:181-95. 
JACC Vol. 5. No.2 
February 1985:326--32 
7. Schwartz AB. Don Michael TA. Botvinick EH. Ishimori T. Parmley 
WW. Chatterjee K. Variability in coronary hemodynamics in response 
to ergonovine in patients with normal coronary arteries and atypical 
chest pain. 1 Am Coli Cardiol 19!O;I:797-803. 
8. Roizen MF. Moss J. Henry DP. Weise V. Kopin IJ. Effect of general 
anesthetics on handling and decapitation induced increases in sym-
patho-adrenal discharge. J Pharmacol Exp Ther 1978;204: 11-8. 
9. Loomis ME. An enzymatic fluorometric method for determination of 
lactic acid in serum. J Lab Clin Med 1961:57:966-9. 
10. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd 
cd. New York: Academic. 1977. 
II. Crawford MH. Sorensen SG. Richards KL. Sedums M. Demonstration 
of combined vasodilator-inotropic effects of RMI 17043 in patients 
with reduced left ventricular performance (abstr). Clin Res 
1982;30:866A. 
12. Kereiakes DJ. Viquerat CE, Lanzer P, Botvinick EH. Chatterjee K, 
Parmley WW. Mechanisms of improved left ventricular function with 
MDL 17043 in heart failure (abstr). Circulation 1983;68(suppllll):l1l-
373. 
13. Martin JL. Likoff MJ. Janicki JS. Laskey W. Hirshfeld JW. Weber 
KT. The cardiotonic agent MDL 17043 and myocardial energetics in 
advanced cardiac failure (abstr). Circulation 1983;68(suppl 111):111-
127. 
14. Chidsey AC. Braunwald E. Morrow AG. Catechobmine excretion 
and cardiac stress of norepinephrine in congestive heart failure. Am 
J Med 1965;39:442-51. 
15. Thomas lA. Marks BH. Plasma norepinephrine in congestive heart 
failure. Am J Cardiol 1978;41;233-43. 
16. Minami M. Yasuda H, Yamazaki N. et al. Plasma norepinephrine 
concentration and plasma dopamine-beta-hydroxylase activity in pa-
tients with congestive heart failure. Circulation 1983;67: 1324-9. 
l
1 8
.
l
J il 83 1
1u r
e
o p.
llll):llI
c
la
J
